2seventy bio, Inc. (NASDAQ:TSVT) Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. reduced its stake in 2seventy bio, Inc. (NASDAQ:TSVT) by 7.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 413,599 shares of the company’s stock after selling 35,679 shares during the period. Charles Schwab Investment Management Inc. owned 0.80% of 2seventy bio worth $1,952,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in TSVT. SkyView Investment Advisors LLC raised its holdings in 2seventy bio by 25.0% during the second quarter. SkyView Investment Advisors LLC now owns 12,500 shares of the company’s stock worth $48,000 after purchasing an additional 2,500 shares in the last quarter. Nisa Investment Advisors LLC acquired a new position in shares of 2seventy bio during the 2nd quarter valued at $52,000. GSA Capital Partners LLP bought a new stake in shares of 2seventy bio in the 3rd quarter worth $64,000. Intech Investment Management LLC acquired a new stake in shares of 2seventy bio in the third quarter valued at $69,000. Finally, SG Americas Securities LLC bought a new position in 2seventy bio during the third quarter valued at about $80,000. 93.90% of the stock is currently owned by institutional investors.

2seventy bio Stock Down 0.3 %

NASDAQ:TSVT opened at $3.26 on Tuesday. The business’s 50-day moving average price is $4.25 and its 200 day moving average price is $4.35. 2seventy bio, Inc. has a 52-week low of $2.89 and a 52-week high of $6.40. The firm has a market cap of $168.18 million, a P/E ratio of -1.75 and a beta of 1.69.

2seventy bio Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.